Harnessing the power of cell and gene therapy in oncology
By 2029, the global cell and gene therapy market is projected to be worth more than $81bn, according to GlobalData’s…
By 2029, the global cell and gene therapy market is projected to be worth more than $81bn, according to GlobalData’s…
HPAPIs offer crucial advantages in treatments for serious and complex diseases, such as cancer and autoimmune disorders. Designed to target…
Recent years have seen a promising trend: the application of technology to revolutionise patient engagement and retention strategies. From mobile…
Unlocking the potential of T cells offers hope to a range of patients with serious diseases, such as cancer, and…
In a challenging CDMO framework, Indena has acquired the experience and the equipment to handle high potent NCEs and commercial…
Oligonucleotides have long been heralded as a revolutionary therapeutic – but key issues surround manufacturing at scale and the sustainability…
Medicinal cannabis has been found to have significant benefits for patients with a variety of conditions. Improvements have been observed…
Indena CDMO origin: Founded in 1921 by Carlo Boccaccio Inverni and Biagio Alberto Della Beffa and headquartered in Milan, Indena…
Indena offers custom development services by leveraging the expertise of a specialised team that’s devoted to designing and developing processes…
The promise of decentralised clinical trials (DCTs) was recognised during Covid-19, but in the following years, sponsors and contract research…